About Chiesi Pharmaceuticals
Chiesi Pharmaceuticals is a Healthcare company based in Parma (Italy) founded in 1935. Developer of drugs for respiratory, neonatology, rare disease and special care therapeutic areas. Chiesi Pharmaceuticals has completed 6 acquisitions, including Amryt Pharma, Atopix Therapeutics and Cornerstone Therapeutics. Its chief executive, as recorded, is Giuseppe Accogli. Its website chiesi.com draws about 112 thousand monthly visits. Its focus areas include Diversified Pharmaceuticals.
Company details
Founded in 1935 in Parma, Italy, Chiesi Pharmaceuticals operates in the pharmaceutical sector, with a focus on therapeutics for respiratory conditions, neonatology, rare diseases, and special care. Respiratory programs target asthma and chronic obstructive pulmonary disease through new chemical entities and reformulated anti-inflammatory and bronchodilator treatments. In neonatology, Curosurf is advanced for neonatal respiratory distress syndrome in late-stage trials.
- Headquarters Parma, Italy
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website chiesi.com
- Social LinkedIn X Facebook
- Latest Funding Round$437.48K (USD), Grant
Nov 2023
- Investors
- Investments & AcquisitionsAmryt Pharma
& 5 more
Funding Insights of Chiesi Pharmaceuticals
- Total Rounds 3
- Last Round Grant — $437,476
- First Round $193,543
(Jul 2019)
- Investors Count 1
All 3 funding rounds of Chiesi Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | $437,476 | Grant | – | – | |
| Jan 2020 | $1.04M | Grant | – | – | |
| Jul 2019 | $193,543 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Chiesi Pharmaceuticals
Chiesi Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Chiesi Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Chiesi Pharmaceuticals
194 people are tracked at Chiesi Pharmaceuticals (78 in leadership, 8 in board & advisors, 108 in team).
| Name | Role | Group |
|---|---|---|
Giuseppe Accogli | CEO | Leadership |
Mike Gordon | Group General Counsel, Executive Vice President- Group Legal & Compliance | Leadership |
Christine Hood | Head Of Global Learning | Leadership |
Marco Camin | Head of Global HRIS & HR Analytics | Leadership |
Lucia Santambrogio | Lead HR Business Partner, Global Franchises AIR & CARE | Leadership |
Arnaldo Ghiretti | Vice President Global Hr Data Analytics And Labour Law | Leadership |
Akis Andrianos | Head Of Global Business Development Air | Leadership |
Laura Fois | HR Business Partner Corporate Functions | Leadership |
Heather McColl | Head Of Global Reward & Performance | Leadership |
Giorgio Cavalleri | Vice President Hr, Region China And International | Leadership |
Alberto Alinovi | Sr. Director, Global Financial Planning & Analysis | Leadership |
Alessandra Capuzzi | Vice President Hr, Europe Top 5 | Leadership |
Marco Vecchia | Group General Counsel Head Of Legal & Corporate Affairs | Leadership |
Michelle Soriano | Head of Franchise Air | Leadership |
Nitin Gandhi | Vp, Strategy, Sustainability & Growth (ssg) | Leadership |
Matt Wiggetts | Vice President, Legal & Compliance Europe Top 5 | Leadership |
Chiara Travagin | Head Of Global Communications, Rare Diseases | Leadership |
Irene Pasquali | Head Of Global Business Development, Respiratory | Leadership |
Filiz Balcay | Mid-Size Europe Region Head | Leadership |
Stefano Cottignoli | Svp, Head Of Global Business And Corporate Development | Leadership |
174 more people are available in the full profile.
Complete people profiles for Chiesi Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Chiesi Pharmaceuticals
Chiesi Pharmaceuticals has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Amryt Pharma, Atopix Therapeutics and Cornerstone Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapies for hereditary angioedema and diabetic macular edema based on small molecule plasma kallikrein inhibitors | kalvista.com | Cambridge, United States | 2011 | Apr 2026 | •••• | |
Therapeutics for rare dermatological and orphan diseases are developed. | amrytpharma.com | Dublin, Ireland | 2015 | Jan 2023 | $1.48B | |
Online platform for the purchase of dietary supplements | nhco-nutrition.com | Biot, France | 2008 | Aug 2018 | •••• | |
Medicines to treat atopic dermatitis and severe asthma | atopixtherapeutics.com | Abingdon, United Kingdom | 2012 | Nov 2016 | $80.37M | |
Pharmaceutical products for respiratory markets are developed and commercialized. | crtx.com | Cary, United States | 2003 | Feb 2014 | •••• | |
Enzyme replacement therapies for the treatment of lysosomal storage diseases such as Alpha-Mannosidosis, Krabbe disease. | zymenex.com | Hilleroed, Denmark | 1998 | Aug 2013 | •••• |
Complete acquisition details for Chiesi Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Chiesi Pharmaceuticals
9 dated milestones of Chiesi Pharmaceuticals across 91 years, from founding to its latest funding, stage changes and deals.
- Founded Chiesi Pharmaceuticals is founded.
- Acquisition Acquires Zymenex.
- Acquisition Acquires Cornerstone Therapeutics.
- Acquisition Acquires Atopix Therapeutics.
- Acquisition Acquires NHCO Nutrition.
- Funding First funding round of $194K.
- Acquisition Acquires Amryt Pharma.
- Funding Latest funding round, Grant, of $437K.
- Acquisition Acquires KalVista.
Web traffic of Chiesi Pharmaceuticals
The website of Chiesi Pharmaceuticals (chiesi.com) receives about 112.3K visits a month and ranks #413,363 among all websites worldwide, #367 in Biotechnology and Pharmaceuticals.
- Monthly visits112.3K
▲ 43.2% vs previous month
- Unique visitors38.1K
per month
- Global rank#413,363
among all websites
- Category rank#367
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.7
- Average visit59 sec
- DevicesDesktop 52% · Mobile 48%
Websites whose visitors overlap most with Chiesi Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
chiesigroup.com | chiesigroup.com | 100% | – | ||
chiesiusa.com | chiesiusa.com | 84% | #1,397,563 | – | |
alexionpharma.com | alexionpharma.com | 79% | – | ||
| recordatirarediseases.com | 75% | #6,153,837 | View details | ||
| proclinical.com | 75% | 63.8K | #560,331 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Chiesi Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chiesi Pharmaceuticals
Complete news archive for Chiesi Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chiesi Pharmaceuticals
Chiesi Pharmaceuticals was founded in 1935 and raised its 1st funding round 84 years after it was founded.
Chiesi Pharmaceuticals is headquartered in Parma, Italy. It is registered at Parma, Emilia-romagna, Italy.
Giuseppe Accogli is the CEO of Chiesi Pharmaceuticals, as recorded in our data.
Founded in 1935 in Parma, Italy, Chiesi Pharmaceuticals operates in the pharmaceutical sector, with a focus on therapeutics for respiratory conditions, neonatology, rare diseases, and special care. Respiratory programs target asthma and chronic obstructive pulmonary disease through new chemical entities and reformulated anti-inflammatory and bronchodilator treatments. In neonatology, Curosurf is advanced for neonatal respiratory distress syndrome in late-stage trials.
Chiesi Pharmaceuticals has made 6 acquisitions, including Amryt Pharma, Atopix Therapeutics, and Cornerstone Therapeutics.
Chiesi Pharmaceuticals has 1 investor. Key investors include European Union.
The website of Chiesi Pharmaceuticals receives about 112 thousand visits a month and ranks #413,363 among all websites worldwide.